Effect of in vivo GM-CSF therapy on PBM 5-LO and FLAP expression in AIDS subjects. PBM were isolated on day 1, day 4, and day 8 of the study protocol, as described in Materials and Methods. Equal amounts (20 μg of protein) of crude cellular lysate from PBM were subjected to immunoblot analysis for 5-LO and FLAP. Top panel, representative autoradiograph of a Western blot demonstrating the amount of 5-LO (A) and FLAP (B) in PBM from HIV-infected subjects on protocol day 1, 4, and 8. Lower panel, relative expression of 5-LO (A) and FLAP (B) in PBM from HIV-infected subjects treated with GM-CSF, as assessed by densitometry and expressed as a percent of values derived from day 1 PBM. n = 9, *P = .05.